| |
EDITOR
Bruce H. Thiers, MD
Medical University of South Carolina
Charleston, South Carolina
DEPUTY EDITOR
Dirk M. Elston, MD
Geisinger Medical Center
Danville, Pennsylvania
EDITORIAL OFFICE
Melissa Derby, Managing
Editor
Journal of the American Academy of Dermatology
482 Southbridge St, Ste 266
Auburn, MA 01501
Phone: 508-476-2724;
Fax: 508-476-7479
E-mail: mderby@aad.org
PUBLISHER
Elsevier Inc.
11830 Westline Industrial Dr.
St.
Louis, MO 63146-3318
Susan M. Kell, Senior Issue Manager
Phone: 215-239-3380; Fax: 215-239-3388
E-mail: s.kell@elsevier.com
Information for Authors
All manuscripts must be submitted via the Elsevier Electronic System (EES) ( http://ees.elsevier.com/jaad/
).
The Information for Authors undergoes continuous revision. The most current version can be found at www.eblue.org.
All manuscripts for the Journal of the American
Academy of Dermatology must be submitted electronically
through the Web-based
EES program. EES may be accessed by visiting http://ees.elsevier.com/jaad/ . The site provides instructions for
manuscript
submission as well as a tutorial for authors.
Word, WordPerfect, RTF, and Text files will be accepted;
Word and WordPerfect are preferred.
All tracking and
follow-up will be done through EES
( http://ees.elsevier.com/jaad/). Questions about the
program may be
addressed to
mderby@aad.org. All manuscript submissions must include the copyright
transfer form, the conflict of interest
disclosure form, the
authorship statement (attestation) form, and the manuscript
submission checklist. These forms can be copied from
the
January or July issues of the Journal and/or downloaded
from either our Web site ( http://www.eblue.org ) or
EES ( http://ees.elsevier.com/jaad/ ). Please scan the completed forms and upload them to EES with your submission. If this
presents a problem, please contact Melissa Derby at mderby@aad.org.
Editorial policies. The Journal
of the American Academy
of Dermatology is a refereed journal designed to meet
the continuing education needs of the Academy members
and the international dermatologic community. The Journal
bases its policies on the guidelines set forth by the International
Committee of Medical Journal Editors ( http://www.icmje.org ).
Disclaimer.
Statements and opinions expressed in
the articles and
communications herein are those of the author(s) and not
necessarily those of the Editor(s), publisher, or Academy.
The Editor(s), publisher, and Academy disclaim any responsibility
or liability for such material and do not guarantee,
warrant, or endorse
any products or services advertised in this
publication, nor do they guarantee any claim made by
the manufacturer of such products or
services.
Conflict of interest. The Journal requires all authors to
acknowledge, in the comments section of EES ( http://ees.elsevier.com/jaad/
), all funding sources
that supported their work as well as all institutional or
corporate affiliations of the authors. The title
page must
also include a publishable statement disclosing any
associations, current and over the past
5 years, that might pose a conflict
of interest. These
include but are not limited to employment, royalties, consultant arrangements with a commercial entity, stock
or other equity
ownership, stock options, patent licensing arrangements,
payments for conducting or publicizing a product or study, or
consulting relationships with investment companies. In
addition, authors are required to disclose similar associations
with companies
that make a competing product. When
no conflicting or competing interests are present, this should be indicated in the publishable disclosure
statement. If the authors have competing
or conflicting interests that cannot be disclosed in publishable
statements, authors should
list them in the comments section
of EES ( http://ees.elsevier.com/jaad/ ).
They should also explain these interests as well
as the reason for
the need for confidentiality in a statement to the Editor. The
Editor asks each reviewer to disclose any competing
interests
or conflicts of interest that might interfere with one's objectivity (or to recuse oneself from acting as a reviewer). The
Editors and members of
the editorial staff have registered their competing interests,
if any, with the officers of the American Academy
of Dermatology. The Editors and members of the editorial staff will ensure that all conflicts are appropriately resolved. Conflicts that
cannot be appropriately resolved will result in rejection of the manuscript or review. Undisclosed conflicts may result in sanctions
to include published statements of retraction or removal of a manuscript from the archived journal table of contents and Medline database.
An authorship statement and conflict of interest
statement must be submitted with each manuscript. Both forms are included in the
January and July issues of the Journal (see last page of
Contents for page number) and are available for download
from the JAAD
Web site( http://www.eblue.org ).
Authorship. The Journal's authorship criteria are adapted
from those
of the International Committee of Medical
Journal Editors and are delineated on the Authorship Statement,
which must be signed by each
author.
Role of writers, "ghost writers," and other "third parties"
involved in manuscript development and production: The
involvement, nature of involvement, and affiliation or support
of any medical writers, "ghost writers," or other individuals
or companies
or third parties participating in the development or writing of any papers must be noted and explained in the
cover letter and in a
publishable statement on the manuscript
title page. (This does not include tasks such as typing or
photocopying.) This statement will
be published as part of the first-page
footnotes. All individuals involved in the preparation
and writing of each paper who meet the
JAAD's authorship
criteria (see our Authorship Statement) must be listed as
authors. The names, highest academic degree, and affiliations
of any persons who contributed to writing the paper or
analyzing the data who do not meet authorship criteria must
be included in the
paper's Acknowledgements along with a
disclosure of any pertinent conflicts of interest. Individuals
listed in the Acknowledgements because
of such contributions
to the work should provide written consent. The use of "ghost writers" or any author employed by an entity with
a commercial interest in any product discussed is rarely appropriate for any manuscript and is strictly prohibited for any CME-accredited
activity.
Special requirements for studies involving live
human or animal subjects. Studies involving live human
or animal
subjects must have been approved by the authors'
Institutional Review Board or its equivalent. A copy of the
IRB approval letter must
be included with the submission
or sent to the Journal office under separate cover. If applicable,
IRB approval must be mentioned
in the methods
section of all manuscripts. Patients must not be identified by name
or initials; numbers should be used. No other information,
including clinical photos or family trees, from which a
patient could be identified is permitted unless express
written permission from
the patient/family is provided at
the time of manuscript submission. All clinical investigations
must have been conducted according to
the Declaration of
Helsinki principles. If the Methods section is not sufficiently
clear, authors may be asked to provide the editors
with a
copy of IRB-approved research protocols for the use of our
reviewers.
Special requirements for submission of survey
research.
Submissions of survey research must include: 1.
A copy of the letter documenting Human Subject Institutional
Review Board (IRB) approval.
2. A copy of the survey
instrument. (The editors, in consultation with the authors,
will determine if the survey instrument should be
published
and whether it should be published as an online-only
Appendix.) The manuscript's Methods section must: 1. Attest
that the use
of any proprietary sampling contact information
(eg, mailing list) was approved by its owner. 2. Provide IRB
protocol approval number
and date. 3. Describe how the
survey instrument was developed and piloted, and whether/
how the survey was validated. During the review
process,
editors and reviewers may request a copy of the approved
study protocol to aid in their evaluation of the study.
Randomized
trials. Randomized trials must be submitted
in a format consistent with the CONSORT statement,
along with a completed CONSORT manuscript
submission
checklist. The word "random" or "randomized" should be in
the title. The updated CONSORT guidelines can be accessed
by visiting
http://www.consort-statement.org . A copy of the "CONSORT Checklist for Authors Submitting
Reports of Randomized Controlled
Trials" may be downloaded
from the JAAD Web site ( http://www.eblue.org ).
Any reports of clinical trials submitted after
January 1, 2008 must be registered by the time of submission; any study that enrolled the first patient after January 1, 2008 must have
been prospectively registered, ie, registered before the first patient was enrolled. The registry must meet ICMJE criteria (available
at http://www.icmje.org ). The registry at http://www.clinicaltrials.gov meets such requirements. When submitting
a manuscript that reports a clinical trial, authors are asked to provide the date the first patient enrolled, the date the study was
registered, and the registration number.
Priority claims, "firstedness." Please do not claim that your report is the first
reported case. If such a claim is deemed necessary, authors should explain their reasoning in the cover letter and provide a detailed
Appendix describing how they came to this conclusion. Describe search strategies, search terms, databases queried, and how far back
these were checked. Also list textbooks and monographs that were searched to substantiate the claim.
Trade names. Trade names
and brand names of drugs and devices may not be used in the title of the paper. They may appear only once in the paper and should be
placed in parentheses along with their manufacturer and the manufacturer's location following the first mention of the generic name in
the text. Thereafter, only generic names should be used throughout the article.
On brevity and other matters of style.
Brevity is appreciated. Authors should avoid repeating the same information in the abstract, introduction, and discussion.
Copyright transfer. In accordance with the Copyright
Act of 1976, which became effective January 1, 1978, the
following statement
signed by
each
author must accompany
the manuscript submitted: "I, the undersigned
author, transfer all copyright ownership
of the manuscript
referenced above to the American Academy of Dermatology,
in the event the work is published. I warrant that the
article
is original, does not infringe upon any copyright or
other proprietary right of any third party, is not under
consideration by another
journal, and has not been published
previously. I have reviewed and approve the submitted
version of the manuscript and agree to its
publication
in the Journal of the American Academy of Dermatology." A
copyright transfer form is included in the January and
July
issues of the Journal (see last page of Contents for page
number) and may be downloaded from the JAAD Web site ( http://www.eblue.org
). Author(s) will be consulted, whenever possible, regarding
republication of material.
Special Subject Repositories: Certain
repositories such as PubMed Central ("PMC") are authorized under special arrangement with Elsevier to process and post certain articles,
such as those funded by the National Institutes of Health, under its Public Access policy (see elsevier.com for more detail on the policy).
Articles accepted for publication in an Elsevier journal from authors who have indicated that the underlying research reported in their
articles was supported by an NIH grant will be sent by Elsevier to PMC for public access posting 12 months after final publication. The
version of the article provided by Elsevier will include peer-review comments incorporated by the author into the article.
Sections/article
type guidelines
Continuing Medical Education (CME): In-depth, substantiated, educational articles presenting core information
for the continuing medical education of the practicing dermatologist. CME articles should not be simply reviews but should present new
information not readily available in textbooks. In order to avoid duplication, authors may wish to contact the managing editor (mderby@aad.org)
early on in the development of the article. A bulleted capsule summary should outline the clinical significance of the article (see "Preparation
of Manuscripts"). In addition, bulleted key points should precede each major section Summary tables should be included when possible,
as should separate algorithms for evaluation and management when appropriate. Recommended tests should have an impact on therapy and
should be supported by outcomes data.
The level of evidence should be cited whenever recommendations are made. Level IA evidence
includes evidence from meta-analysis of randomized controlled trials; level IB evidence includes evidence from at least one randomized
controlled trial; level IIA evidence includes evidence from at least one controlled study without randomization; level IIB evidence includes
evidence from at least one other type of experimental study; level III evidence includes evidence from nonexperimental descriptive studies,
such as comparative studies, correlation studies, and case-control studies; and level IV evidence includes evidence from expert committee
reports or opinions or clinical experience of respected authorities, or both. All therapeutic recommendations should be accompanied by
a table indicating their level of evidence, with a definition of the different levels included as a footnote.
Authors must provide
3 learning objectives that identify practice gaps pertinent to the material being presented, and, in their cover letter, specify how
the gaps were identified. The learning objectives should address those practice gaps. The learning objectives should be measurable and
written in active terms. The following verbs are suggested for consideration in writing objectives: apply, assess, categorize, choose,
compare, diagnose, differentiate, distinguish, manage, measure, prescribe, recognize, select, test, treat, use, and utilize. Learning
objectives should be listed in the following format: Following this activity, the participant will be able to: 1. ____________; 2. ____________;
and 3. ____________. (For example, Following this activity, the participant will be able to: 1. diagnose fungal skin diseases more effectively;
2. order the most appropriate test for herpetic skin infections; and 3. select the best treatment for the patient with impetigo herpetiformis.)
Note that the learning objective must specify a change in physician behavior, not simply knowledge that was acquired.
As an example
for a CME article on tropical dermatology, a pertinent practice gap might be that dermatologists believe they lack the skill to diagnose
leishmaniasis, although they may now see it in travelers and soldiers returning from overseas. This gap became evident from discussions
with a group of local dermatologists during a grand rounds session where such a patient was presented. Thus, one appropriate learning
objective might be: At the completion of this activity, the participant will be able to... "take the appropriate steps to confirm the
diagnosis of leishmaniasis."
In order to qualify for CME credit, authors must provide 2 clinical vignettes, each followed by 2
or 3 questions, that evaluate clinical competence acquired as a result of the CME activity. The questions should reflect appropriate
clinical practice rather than simply testing factual knowledge. Suitable questions assess the learner's ability to diagnose or treat
a condition appropriately after reading the CME article. Guidelines for question writing can be found at http://www.eblue.org/webfiles/images/journals/ymjd/dos_donts.pdf
.
Original Articles: Original, in-depth clinical and investigative laboratory research papers. A structured abstract
and capsule summary should be included (See "Preparation of Manuscripts"). Authors of randomized control trials are strongly urged to
follow the guidelines presented in the CONSORT statement
( http://www.consort-statement.org/). Similar guidelines for authors
of epidemiologic studies are included in the STROBE statement
( http://www.strobe-statement.org/Checklist.html).
Reviews:
A current review of a disease or treatment.
Dermatologic Surgery: Articles emphasizing the surgical
aspect of dermatology.
A structured abstract and capsule summary should be included (See "Preparation of Manuscripts").
Dermatopathology: Articles
emphasizing the histopathological changes in skin disease. A structured abstract and capsule summary should be included (See "Preparation
of Manuscripts").
Editorials/Commentaries: Brief, provocative, opinionated communications, not necessarily documented, on
a limited subject.
Letters: Notes & Comments, Research Letters, and Case Letters: The Letters department has three sections.
Letters
commenting on material previously published in the Journal
will be considered for the Notes & Comments section.
New or preliminary research findings may be considered for publication as Research Letters. Conclusions based on uncontrolled trials
and/or limited experience should be stated in appropriately tentative terms. Concise descriptions detailing one or two patients, early
reports of therapeutic trials in one or several patients, and early reports of new drug reactions will be considered for the Case Letters
section. Repetition of introductory, textbook type information should be avoided. Manuscripts should center on the case at hand, and
should not take the form of a lengthy "Case and Review." All patient information in Case Letters must be adequately de-identified. If
identifying information or figures are included, express written permission from the patient(s) must be provided at the time of manuscript
submission. Letters must not exceed 500 words and should not cite more than five references. Up to two figures or tables may be included.
Letters on articles that have appeared in the Journal will be sent for response to the authors of the article being commented
upon. This response may be published or sent directly to the commentator at the discretion of the editor. Questions or comments that
could be addressed directly to authors (including complaints about missed citations) should be sent directly to the author, rather than
involving the Journal as an intermediary.
Book Reviews: Books and monographs (domestic and
foreign) will be reviewed
depending on their interest and
value to subscribers. Send books to the Editor, Bruce H. Thiers, MD, Journal of the American Academy
of Dermatology,
482 Southbridge St,
Ste #266,
Auburn, MA 01501. No books will be
returned. Journal guidelines for writing
book reviews are available online ( http://www.eblue.org/article/S0190-9622(08)00647-6/fulltext ).
Images in Dermatology:
This an online-only feature that consists of 1-3 clinical or histologic images along with a short (100 word or less) description of any
relevant history. Short (up to 1 minute) video clips are also acceptable. Included are 3 questions, each with 5 answer choices. Each
of the 5 choices must be accompanied by a 1 or 2 sentence discussion explaining why it is correct or incorrect. The discussion of all
5 choices is limited to a total of 250 words for each question. Authors may cite up to 5 references. The submitted title, consisting
of less than 8 words, should be descriptive and not indicate the diagnosis or correct answer choice. All submissions must be through
EES. If identifying information or figures are included, express written permission from the patient must be provided at the time of
manuscript submission. Material may not have been submitted or published elsewhere. If you are currently working on a submission for
this feature, please contact Melissa Derby at mderby@aad.org for an example of the desired format.
Video
For editorial and peer review of an initial submission, submit videos according to the following specifications:
-
- Acceptable
file formats: MPEG-1 or MPEG-2 (.mpg), Quicktime (.mov), or Compuserve GIF (.gif). Please contact the publisher about the use of other
formats.
- Maximum file size: 10MB
- Maximum length: 8 minutes
- Verify that the videos are viewable in QuickTime
or Windows Media Player.
- Concise legends (typed on a separate page) must accompany each video clip or computer graphic presentation.
- All videos or graphics submitted must be of the highest quality possible.
An original, edited CD-ROM
or DVD-R in Windows-compatible format will be the standard format for submission of videos and computer graphics (ie, slide presentations
with or without animation).
Three copies of the disk containing the video/computer graphics should be submitted by mail or courier
when the manuscript is submitted. Be sure to include the manuscript title and date of submission so that the disks can be crossreferenced
to the manuscript submission. Please indicate the video component on the submission cover page.
If the article is accepted for publication,
the video will be digitized and permanently archived on the Journal of the American Academy of Dermatology website ( http://www.eblue.org/
).
Supplements
The Journal follows the guidelines for supplements
established by the International Committee
of Medical
Journal Editors. These guidelines are included in the document
entitled "Uniform Requirements for Manuscripts Submitted
to
Biomedical Journals," which can be found at
http://www.icmje.org . Supplements undergo peer review
and are processed in
the same fashion as regular submissions
to the Journal. All manuscript submission requirements,
including clear disclosure of
authorship
contributions, must be satisfied for each paper. Inquiries
about proposed supplements should be directed to the
Editor before
submitting the supplement. Please note Journal policy on the use
of the word "unrestricted" in the description of educational
grants:
The use of the term "unrestricted" will be limited to
situations in which the granting institution has no influence
on the selection
of the subject, speakers, or authors. In
circumstances in which the granting institution has had such
influence (as, for example, in
organizing a symposium or
supplement on a particular subject), it is nonetheless
required that the granting organization have no influence
over the content of the articles. It is also understood that the
authors assume full responsibility for the content of the
articles and
for complete disclosure of all funding sources,
potential conflicts of interest, role of any sponsor, and role
of any third parties involved
in the preparation or writing of
the manuscripts.
Electronic publication at www.eblue.org
Articles in Press: Prior to print publication, most Original Articles are now "published online" in our Articles in Press section
in the JAAD Online at www.eblue.org. Some articles are published online only
in our JAAD Online
section ("online only publication"). Please note that online
publication is considered a bonafide form of publication
and can be cited using the DOI number located in the footnotes on the first page of each article.
The full content of each regular
monthly issue is
routinely posted online at www.eblue.org.
PREPARATION
OF MANUSCRIPTS
Original manuscripts will be considered for publication.
Correct preparation of the manuscript will expedite
the
review and publication procedures. Please note the
following requirements.
The original page-numbered copy of the manuscript
must be double-spaced. The title page should be numbered page 1. Please line number all submissions before creating the PDF. This
continuous line numbering will help our reviewers with writing their comments and should speed the peer-review process. To add line numbers
to your Word manuscript file, select File/Page Setup/Layout/Line Numbering/Add line numbering/Continuous, and save the changes.
Style
Manuscripts must conform to acceptable English usage.
Consult the latest edition of The Chicago Manual of Style
by
The University of Chicago Press or the Manual of Style by
the American Medical Association for current usage. Abbreviations
must be limited primarily to those in
general usage. Weights and measurements must be
expressed in metric units. Temperatures must be
expressed in degrees centigrade.
Title page: On the title page, include the title, authors' full
names, highest earned
academic degrees, and institutional
affiliations and locations. The title page must also include
a statement of all funding sources for
the work as well as
a publishable conflict of interest statement (see above for
details). Designate one author as correspondent (provide
address, telephone and fax numbers, and e-mail address) to
receive communications from the Editorial Office and galley
proofs from the
publisher. The name and address of the
author who will receive reprint requests should be noted if
different from the correspondent. The corresponding
author should promptly inform the managing editor (mderby@aad.org)
of any change in e-mail or mailing
address.
Abstract: Unless otherwise stated, all articles must be
accompanied by a typed, double-spaced abstract not
exceeding
250 words. Abstracts of papers submitted for
publication in the Original Articles, Dermatopathology,
and Dermatologic Surgery
sections should be structured as
follows:
Background: What is the major problem that prompted the
study?
Objective:
What is the purpose of the study?
Methods: How was the study done?
Results: What are the most important findings?
Limitations: What are the limitations of the study?
Conclusion: What is the single most important conclusion?
Key words: A list of 6-10 key words (eg, Key words: sunscreen; UVA protection; UVB protection) should appear after the Abstract.
Classifications:
Select at least 6 classifications to facilitate matching the manuscript with reviewers. You can do this in EES by clicking 'Select Document
Classifications' to open a window containing a list of the classifications pertaining to the Journal. Then click the check-box next to
any classification you wish to select. Click 'Submit' when you are done.
Capsule summary: Papers submitted for publication
in the Continuing Medical Education, Original Articles, Review, Dermatologic Surgery, and Dermatopathology sections must include a capsule
summary of up to 75 words. The capsule summary should be comprised of 3-4 bulleted statements outlining the clinical significance of
the contribution.
Abbreviations and acronyms: Only standard abbreviations
are to be used. Consult Scientific Style and
Format by
the Council of Biology Editors or the Manual of Style by the
American Medical Association. Abbreviations in the
title are
not acceptable and they should be avoided in the abstract whenever
possible. A laboratory or chemical term or a disease process
must be spelled out at first mention, with the acronym or
abbreviation following in parentheses. List all abbreviations
and acronyms
on a separate page.
Histologic/microscopic figures: The legend must specify
stain. Arrows and arrowheads should be
used
freely to clarify findings.
References: Personal communications should not be
cited in the reference list but may
appear parenthetically
in the text. References must be identified in the text by
superscript Arabic numerals in order of their
mention.
The reference list should be typed double-spaced at
the end of the text in numeric sequence. The format should
conform to
that set forth by the International Committee of
Medical Journal Editors and the National Library of Medicine
( http://www.nlm.nih.gov/bsd/uniform_requirements.html
).
Journal titles should conform to the abbreviations in Cumulated
Index Medicus.
EXAMPLES OF REFERENCES
List the first six
authors followed by et al.:
For journal articles:
Kofler H, Wambacher-Gasser B, Topar G, Weinlich G,
Schuler G,
Hintner H, et al. Intravenous immunoglobulin
treatment in therapy-resistant epidermolysis bullosa acquisita.
J Am Acad Dermatol 1997;36:331-5.
For books:
Hunt TK, editor. Wound healing and wound infection:
theory and surgical practice. New York: Appleton-Century-
Crofts; 1980.
For chapters in books:
McNutt NS, Fishman PM. Metastatic tumors. In: Farmer
ER, Hood AP, editors.
Pathology of the skin. Norwalk
(CT): Appleton & Lange; 1990. p. 465-78.
For electronic media:
Bhatia A, Prakash S.
Topical phenytoin for wound
healing. Dermatology Online Journal. Available at:
http://dermatology.cdlib.org . Accessed November
3,
2004.
For articles published online ahead of print:
Adebamowo CA, Spiegelman D, Danby FW, Frazier AL, WillettWC,
Holmes MD. High school dietary dairy intake and teenage acne. J Am Acad Dermatol doi:10.1016/ j.jaad.2004.08.007. Published online October
29, 2004.
Illustrations and tables: Tables, figures, and legends
should supplement, not duplicate, the text. Clinical
photographs should be of high quality without distracting backgrounds. Please visit our website ( http://www.eblue.org )
for examples of acceptable
and unacceptable illustrations.
A reasonable
number of halftone photographs and line drawings will be
published at no extra charge to the author. Color illustrations
will be reviewed by the Editor and those considered
appropriate will be published free of charge to the authors.
Figures must be cited
in the text and numbered in order of
mention. Figures must have an arrow marking the top edge
and they must be numbered consecutively
(ie, 1, 2, 3).
Multi-part figures must be marked clearly (ie, 1A, 1B, 1C).
For graphics files, use Adobe Photoshop and save the files
in
either TIF or EPS format. DO NOT SUBMIT figures in
PowerPoint or Excel formats. If they have not already done
so, authors will be
contacted to provide print-quality figures
after their articles have been accepted.
Policy on image alteration:
Any image alteration from the original using programs such as Photoshop must be explained and justified in the legend.
Black and
white graphs must be legible and clearly
printed. The fill for bar graphs or pie charts should be
distinctive; avoid shading or dotted
patterns. Use thick, solid
lines and bold, solid type. Place lettering on a white background;
avoid reverse type (white lettering on
a dark background).
All lettering must be done professionally and should
be in proportion to the drawing, graph, or photograph.
Typewritten
or freehand lettering is unacceptable. Consistency
in size within the article is strongly preferred. Any
special instructions regarding
sizing should be clearly noted.
For color photographs, if prints have been enhanced,
a preference for reproduction should be
noted.
The quality of the reproduction depends entirely
on the quality of the illustrations submitted.
Please note that 35 mm transparencies
are normally enlarged
to twice their original size. If it is important to deviate
from this standard, please indicate when file material
is
submitted. Top for each print (and transparency) must be
noted.
Patient consent must accompany recognizable
photographs
of patients at the time of submission. Photographs and text (such as details in the case report or genetic pedigree) must be deidentified
to protect patient confidentiality unless patient consent has been documented. In the event that patient consent has not been documented,
please crop the photo and/or obstruct the eye region in such a manner that the patient cannot be recognized. The altered figure
must be unidentifiable unless documentation of patient consent is provided.
Figures may be submitted in electronic format. All images
should be at least 5 inches wide. Images should be provided in TIF, EPS, or JPEG format. Graphics software such as Photoshop
and Illustrator,
not presentation software such as Microsoft Word, PowerPoint, CorelDraw, or Harvard Graphics
, should
be used in the creation of the art. Color images must be CMYK and at least 300 DPI. Gray scale images should be at least 300 DPI. Combinations of gray scale and line art should be at least 1200 DPI. Line art (black and white or color)
should be at least 1200 DPI.
Legends should be typed double-spaced and inserted after the
references. If an illustration
has been published previously,
full credit to the original source must be given in the legend.
Tables should be self-explanatory
and numbered sequentially in Roman numerals in order of their mention in the text. Tables should be submitted in Word, WordPerfect, RTF,
or Text formats; Word and WordPerfect are preferred. A brief title should be provided for each. If a table, or any data therein, has
been published previously, full credit to the original source must be given in a footnote.
Permissions and patient consent forms: Direct quotations,
tables, or illustrations that have appeared in
copyrighted material must be accompanied upon submission by written
permission for their use from the copyright owner
and the original author along with complete information
as to their source .
Patient
consent forms for publication of recognizable
photographs must be sent to the Editorial Office
upon submission of the article. Patients
must be identified by numbers and/or letters, not by name, initials, or
hospital record number. Institutional consent must also
be available.
Reprints. Reprint order forms will be sent to authors after the manuscript has been accepted. The provision
of reprints by the author is optional.
Procedure for review
The Journal employs a confidential and anonymous
peer review process to evaluate submitted papers for possible publication. A small number of papers are rejected after in-house editorial
review when editors deem that the paper is not appropriate for the Journal or is not of sufficient quality to warrant further evaluation.
The overall acceptance rate is less than 50%.
The author may suggest several reviewers for the manuscript. We will attempt
to use at least one suggested reviewer. The editorial staff will review the manuscript and will ordinarily send it to at least two reviewers.
Reviewers will pay particular attention to scientific accuracy, relevance, novelty, importance, appropriate style, and quality of illustrations.
First decisions (accept, revise, reject) are usually made within four to six weeks; longer delays are possible. Some degree of manuscript
revision should be expected and regarded as constructive. A request to submit a revised manuscript does not guarantee that it will be
accepted, only that it will be reconsidered, perhaps after additional peer review. Because space in the Journal is limited,
the final editorial decision rests not only on the validity of the report and the opinions of the reviewers, but also on the editors'
judgment of a paper's novelty, clarity, importance, and likely degree of interest to the readership.
Expedited review and publication
Authors who feel that their paper should receive expedited
review and/or rapid publication should request it and
explain their rationale
in the Comments section of EES ( http://ees.elsevier.com/jaad/ ). They should also send a separate explanatory e-mail to
the managing editor: mderby@aad.org. The time frame for
rapid review is ordinarily 2 to 4 weeks; for expedited online
publication,
3 to 6 weeks from the date of acceptance of the final
revision. Authors are reminded that as a monthly clinical
journal,
we do not operate on the time frame of a weekly
and do not ordinarily publish "news" items.
Updated June 2010
|
| |
|
